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Abstract
In this study we demonstrate that CD34+ cells derived from human embryonic stem cells (hESCs) have higher smooth
muscle cell (SMC) potential than CD342 cells. We report that from all inductive signals tested, retinoic acid (RA) and platelet
derived growth factor (PDGFBB) are the most effective agents in guiding the differentiation of CD34
+ cells into smooth
muscle progenitor cells (SMPCs) characterized by the expression of SMC genes and proteins, secretion of SMC-related
cytokines, contraction in response to depolarization agents and vasoactive peptides and expression of SMC-related genes in
a 3D environment. These cells are also characterized by a low organization of the contractile proteins and the contractility
response is mediated by Ca2+, which involves the activation of Rho A/Rho kinase- and Ca2+/calmodulin (CaM)/myosin light
chain kinase (MLCK)-dependent pathways. We further show that SMPCs obtained from the differentiation of CD34+ cells
with RA, but not with PDGFBB, can be maturated in medium supplemented with endothelin-1 showing at the end
individualized contractile filaments. Overall the hESC-derived SMCs presented in this work might be an unlimited source of
SMCs for tissue engineering and regenerative medicine.
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Introduction
Vascular smooth muscle cells (VSMCs) have enormous
applications in regenerative medicine [1,2,3]. Studies have
demonstrated that smooth muscle-like cells (SMLCs) can be
derived from bone marrow-[4,5], adipose-[6,7] and umbilical cord
blood-derived stem cells [8]. Due to the easy expansion, human
embryonic stem cells (hESCs) represent an alternative source of
VSMCs particularly for old patients having stem cells with
impaired function. Recent studies reported different strategies to
differentiate hESCs into SMLCs by exposing a monolayer of
undifferentiated hESCs to retinoic acid [9] or a combination of
cell culture medium and extracellular matrix environment
[10,11,12] either in single-hESC- [13], embryoid bodies (EBs)-
[12] or stromal cell- [14] culture conditions. In one case, SMLCs
transplanted subcutaneously in an animal model were able to
contribute for the formation of functional blood microvessels [12].
Despite these advances, several issues remain poorly understood:
(i) what hESC-derived population has the most SMC potential, (ii)
the bioactive molecules involved in the differentiation process, (iii)
the modulatory effect of 3D environments in SMLCs, (iv) the
functionality of the differentiated SMLCs, and (v) the level of
organization of the contractile protein filaments.
Here we evaluate the smooth muscle cell (SMC) differentiation
of different cell populations isolated from human embryoid bodies
grown in suspension for 10 days. The isolated cells were cultured
in media supplemented with several inductive signals, including
platelet-derived growth factor (PDGFBB), retinoic acid (RA),
transforming growth factor beta 1 (TGFb-1) or a combination of
PDGFBB with TGFb-1. We show that CD34
+ cells have higher
SMC potential than CD342 cells and PDGFBB and RA are the
most effective agents to drive the differentiation of hESCs into
smooth muscle progenitor cells (SMPCs). We further demonstrate
that these cells contract and relax in response to SMC agonists or
inhibitors, respectively, and the effect is mediated by Rho A/Rho
kinase- and Ca2+/CaM/MLCK-dependent pathways. In addition,
cells encapsulated in 3D gel scaffolds further differentiate towards
SMC lineage as confirmed by gene analysis. Finally, we show that
Endothelin-1 induces the organization of the contractile protein
filaments.
Materials and Methods
An expanded Materials and Methods section is provided in the
online data supplement (Materials and Methods S1).
hESC culture and embryoid body (EB) formation
Undifferentiated hESCs (passages 27–62; H9, WiCell, Wiscon-
sin, http://www.wicell.org/) were grown on an inactivated mouse
embryonic fibroblast (MEF) feeder layer, as previously described
[12]. To induce the formation of EBs, the undifferentiated hESCs
were treated with 2 mg/mL type IV collagenase (Invitrogen,
http://www.invitrogen.com) for 2 h and then transferred (2:1) to
low attachment plates (Corning, http://www.corning.com) con-
taining 10 mL of differentiation medium [80% KO-DMEM, 20%
fetal bovine serum (FBS, Invitrogen), 0.5% L-glutamine, 0.2% b-
mercaptoethanol, 1% nonessential amino acids and 50 U/
ml:50 mg/ml penicillin-streptomycin solution]. EBs were cultured
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for 10 days at 37uC, 5% CO2 in a humidified atmosphere, with
media changes every 3–4 days.
Isolation and differentiation of CD34+, CD342 and
CD34+KDR2 cells
CD34+ cells were isolated from EBs at day 10 according to a
protocol previously reported by us [12]. For some experiments, the
CD34+ cells were further separated in CD34+KDR2 cells. In this
case, cells were labeled with anti-VEGF R2/KDR-PE antibody
(R&D, http://www.rndsystems.com/), then conjugated with anti-PE
antibody coupled with magnetic beads, and finally the magnetically
labeled cells were separated into CD34+KDR+ and CD34+KDR2
using a MS-MACS column (Miltenyi Biotec, http://www.miltenyi-
biotec.com). Isolated cells were grown on 24-well plates (1.56104
cells/cm2) coated with 0.1% gelatin and containing one of the
following media: smooth muscle growth medium-2 (SMGM-2),
endothelial growth medium-2 (EGM-2) or EGM-2 supplemented
with PDGFBB (50 ng/mL, Prepotech, http://www.peprotech.com/)
or RA (1 mM, Sigma, http://www.sigmaaldrich.com) or TGFb-1
(10 ng/mL, Prepotech) or a mixture of PDGFBB with TGFb-1
(50 ng/mL; 10 ng/mL). Human vascular smooth muscle cells
(hVSMCs, isolated from the arteries of human umbilical cord,
Lonza, http://www.lonza.com) were used as controls for the
differentiation studies. Cells were cultured in SMGM-2 media
(Lonza; until passage 6) being the medium changed every 2 days.
Immunofluorescence analysis
Cells were transferred to gelatin-coated slides containing
differentiation medium, allowed to attach overnight, and then
fixed with 4% paraformaldehyde (Electron Microscopy Sciences,
http://www.emsdiasum.com/microscopy) for 15 min at room
temperature. Cells were blocked with 1% (w/v) BSA and stained
for 1 h with anti-human primary antibodies specific for smooth
muscle a-actin (a-SMA, 1A4, Dako, http://www.dako.com/),
smooth muscle myosin heavy chain (SM-MHC, SMMS-1, Dako)
and calponin (CALP, Calponin1, Santa Cruz Biotec, http://www.
scbt.com/). In each immunofluorescence experiment, an isotype-
matched IgG control was used. Binding of primary antibodies to
specific cells was detected with anti-mouse IgG Cy3 conjugate or
anti-mouse IgG FITC (both form Sigma). Cell nuclei were stained
with 49, 69-diamidino-2-phenylindole (DAPI) (Sigma) and the
slides examined with either a Zeiss fluorescence microscope or
Zeiss LSM 50 confocal microscope.
Reverse transcription-polymerase chain reaction (RT-PCR)
analysis
Total RNA from experimental groups was isolated using a
protocol with TRIzol (Invitrogen) and RNeasy Minikit (Qiagen,
Valencia, http://www1.qiagen.com/). cDNA was prepared from
1 mg total RNA using Taqman Reverse transcription reagents
(Applied Biosystems, CA). Quantitative PCR (qPCR) was per-
formed using Power SYBR Green PCR Master Mix and the
detection using an ABI PRISM 7500 System (Applied Biosystems,
http://www3.appliedbiosystems.com). Quantification of target
genes was performed relative to the reference GAPDH gene:
relative expression = 2[2(Ctsample
2Ct
GADPH
)]. The mean minimal
cycle threshold values (Ct) were calculated from quadruplicate
reactions. Then, the relative gene expression in each experimental
group was normalized to the relative gene expression found in
hVSMCs. Primer sequences are published as supporting informa-
tion (Table S1). For the RT2 ProfilerTM PCR Array, cDNA was
prepared from 1 mg total RNA using the RT2 PCR Array first
strand kit (SABiosciences, http://www.sabiosciences.com/). RT-
PCR assays were performed using the human extracellular matrix
and adhesion molecules RT2 ProfilerTM PCR Array (SABios-
ciences) on an ABI PRISM 7500 System. Data analysis was
performed using analysis software provided by the kit manufacturer.
Intracellular Ca2+ variation measurements
SMCs or hESC-derived cells were loaded with Fura-2 calcium
fluorescent indicator [15] by incubation with 5 mM of the
membrane permeable acetoxymethyl (AM) derivative FURA-2/
AM (1 mM in DMSO, Molecular Probes, Invitrogen) and 0.06%
(w/v) Pluronic F-127 (Sigma), using basal medium (M199, Sigma)
as a vehicle (35 ml/well, not supplemented with serum nor
antibiotics), for 1 h at 37uC in 5% CO2 and 90% humidity. Cells
were then stimulated with 100 mM histamine (Sigma) [16],
1027 M bradykinin (Calbiochem, http://www.merck-chemicals.
com/) [17], 1025 M angiotensin II (Calbiochem) [17], 1025 M
carbachol (AlfaAesar) [6] or 50 mM KCl (Merck, http://www.
merck-chemicals.com) [16] by adding 1 ml of a stock solution. A
detailed methodology for the fluorescence acquisition can be
found on the online data supplement (Materials and Methods S1).
Contractility assays
Agonist-induced contractile activity of the differentiated cells
was evaluated as previously described [6,12]. hECS-derived cells
cultured for 3 passages were washed with DMEM and contraction
was induced by incubating these cells with 1025 M carbachol in
DMEM (Sigma) medium for 30 min. Contraction was calculated
as the difference in cell area between time zero and 30 minutes.
The same microscopic fields were imaged before and after
treatment for contraction analysis. In a distinct experiment, cell
relaxation was induced by incubation with 1024 M atropine
(AlfaAesar) in DMEM for 1 h followed by contraction with
1025 M carbachol. Contraction was calculated as before.
hVSMCs (3rd passage) were used as controls.
Effect of RhoA/Rho kinase- and CaM/MLCK- agonists in
cell contraction and maturation
hVSMCs or hESC-derived SMPCs were treated with the
inhibitor W-7 (12 mg/mL, Sigma) for 30 min and the agonist
U46619 (1 mM, a CAM kinase-agonist) (Cayman Chemicals,
http://www.caymanchem.com) in serum-free M199 medium for 3
days. At the end, cells were characterized for the expression of
SMC markers by immunostaining. Finally, the contraction of
U46619-treated cells was evaluated by embedding the cells in
fibrin gels (3.56104 cells/50 mL) and measuring gel size at time 0
and 14 h by microscopy. This methodology was repeated to
evaluate the effect of Rho kinase-agonist in cell contraction and
maturation. In this case, the cells were exposed to the inhibitor
Y27632 (13 mM) (Cayman Chemicals) and the agonist endothelin-
1 (End-1, 10 nM, Sigma).
Cytokine measurements
Cell culture supernatants were assayed for cytokines using a Bio-
plex human 17-plex panel immunoassay kit (Bio-Rad, http://
www.bio-rad.com) and cytokines concentrations were determined
using Bio-Plex Manager 5, according to manufacturer’s instruc-
tions. Samples and controls were run in triplicate, standards and
blanks in duplicate. A detailed methodology can be found on the
online data supplement (Materials and Methods S1).
Co-culture of hESC-derived SMPCs with hVSMCs
To evaluate the effect of both soluble and insoluble factors,
fluorescently-labeled hESC-derived SMPCs (stained with PKH67
hESC-Derived Smooth Muscle Cells
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dye, Sigma) were plated on top of mytomycin-inactivated hVSMC
cultured on a 24 well plate for 2 days before use. This co-culture
system was maintained for 5 days after which the overall cells were
tripsinized, and fluorescent (PKH67+ cells) cells sorted by a FACS
Aria (BD). The sorted cells were characterized by immunohisto-
chemistry to evaluate the expression and organization of a-SMA,
SM-MHC and calponin filaments.
Culture of SMPCs in three-dimensional gels
Fibrin gels were obtained by the crosslinking of 20 mg/mL
fibrinogen/TBS pH 7.4 in the presence of 50 U/mL thrombin/
TBS pH 7.4 (both from Sigma-Aldrich). Fibrin gels (50 mL) were
prepared by mixing the following components: 10 mg/mL
fibrinogen, 2.5 mM CaCl2, 2 U/mL thrombin and 0.01 mg/mL
aprotinin (Sigma-Aldrich). This solution was allowed to gel at
37uC in 100% relative humidity. hVSMC or hESC-derived
SMPCs (36105) were encapsulated in fibrin gels (50 ml). Cells were
centrifuged and resuspended in the fibrin gel precursor solution
and included in 1 mL sterile syringes with cut tips. Polymerization
was initiated at 37uC and allowed to proceed over 30 min. After
polymerization, the cell constructs were removed from the syringe
and placed in 24-well plates, containing specific medium, for up to
96 h.
Statistical analysis
An unpaired t test or one-way ANOVA analysis of variance with
Bonferroni post test was performed for statistical tests using
SigmaStat. Results were considered significant when P,0.05.
Data are shown as mean 6 SEM.
Results
Effect of initial cell population and inductive signals on
cell proliferation
We evaluated the SMC differentiation potential of three cell
populations isolated from EBs at day 10: CD34+ cells, CD342 cells
and CD34+KDR2 cells (mesenchymal origin [18]) (Figure 1A).
The percentages of CD34+ and CD34+KDR2 cells in EBs were
approximately 2% and 1.7%, respectively, after MACS isolation.
As evaluated by flow cytometry (Materials and Methods S1),
the purity of the cell populations CD34+, CD342, and
CD34+KDR2 was .80%, .98% and .98%, respectively
(Figure 1B). These cells were plated on gelatin coated dishes, at
low density (1.56104/cm2), and cultured on basal media (EGM-2
or SMGM-2) supplemented or not with different inductive signals
to guide their SMC differentiation: PDGFBB (50 ng/mL)
[5,12,19], RA (1 mM) [9,17,20], TGFb-1 (10 ng/mL) [5,21,22]
or a combination of TGFb-1 (10 ng/mL) with PDGFBB (50 ng/
mL) (Figure 1A). These concentrations have been used previously
in the differentiation of stem cells from different origins into
vascular cells [5,9,21].
CD34+ cells cultured on EGM-2 medium supplemented with
PDGFBB presented the highest proliferation (more than 8
population doublings over 20 days), followed by the ones cultured
in EGM-2 medium supplemented with RA (Figure 1C.1).
CD34+ cells grown in EGM-2 medium without PDGFBB or RA
proliferated poorly over 40 days (Figure 1C.1). Interestingly,
CD34+ cells cultured in medium supplemented with TGFb-1 and
PDGFBB had low proliferation suggesting that TGFb-1 inhibited
the effect of PDGFBB. CD34
+KDR2 cells cultured on EGM-2
medium without any supplements proliferated extensively, show-
ing more than 8 population doublings over 20 days (Figure 1C.2).
Similar proliferation potential was observed for CD34+KDR2
cells grown in EGM-2 medium supplemented with RA, but not on
medium supplemented with PDGFBB.
The proliferation rate of CD342 cells was also assessed in the
media formulations tested for CD34+ and CD34+KDR2 cells.
CD342 cells cultured on EGM-2 medium supplemented with
PDGFBB showed the highest proliferation, having more than 8
population doublings over an 18 days period (Figure 1C.3). In
contrast, cells grown in EGM-2 medium supplemented with RA
did show a poor proliferation over more than 20 days.
All taken together, the proliferation potential of the cells was
dependent on the initial cell population and the supplements
added to the basal media.
Effect of initial cell population and inductive signals on
SMC differentiation
Next we evaluated the expression of SMC-specific genes in the
hESC-derived cells (passage 4) by quantitative RT-PCR
(Figure 2). The genes analyzed included: a-smooth muscle actin
(a-SMA), an early marker of SMC differentiation and highly
specific marker for SMCs in adult animals [23]; smooth muscle
myosin heavy chain (SM-MHC), a later marker in SMC
differentiation that seems to be highly restricted to SMCs [24];
calponin and smooth muscle a-22, definitive SMC markers [25].
The gene expression in the hESC-derived cells was normalized by
the corresponding gene expression in hVSMCs.
Undifferentiated CD34+ cells expressed low levels of SM-MHC
(,2.0%), SMa-22 (,1%) and calponin (,2.0%), in most cases
comparable to the levels found in undifferentiated hESCs, and
moderate levels of a-SMA (,10%) (Figure 2). Culture of these
cells in the presence of EGM-2 medium supplemented with
PDGFBB or RA contributed for the up-regulation of SMC genes,
as confirmed by the significant increase in the expression of a-
SMA (.400-fold) and SM-MHC (.1,600-fold) when compared
with undifferentiated CD34+ cells (p,0,05), and hVSMCS (a-
SMA: .39-fold; SM-MHC: .27-fold) (Figure 2). Addition of
TGFb-1, or TGFb-1 plus PDGFBB increased the cellular expression
of a-SMA, SM-MHC, SMa-22 and calponin when compared to
undifferentiated CD34+ cells; however, the expression was one
order of magnitude lower than the one in hVSMCS, suggesting
that the CD34+-derived cells were not fully differentiated into
SMCs.
CD34+KDR2 cells cultured in SMGM-2 medium or EGM-2
medium in the presence or absence of PDGFBB expressed higher
levels of a-SMA (.42-fold), SM-MHC (.150-fold), SMa-22
(.18-fold) and calponin (.2-fold) than undifferentiated CD34+
cells (Figure 2). In addition, these cells showed similar levels of
expression of a-SMA and SM-MHC to the one found in
hVSMCs, suggesting that these cells shared features with SMCs.
In contrast to the CD34+ and CD34+KDR2 cells, CD342 cells
cultured in several media formulations had lower expression of
SMC markers, indicating low efficiency of differentiation into
SMCs (Figure 2). Of note, all the hESC-derived cells previously
described had low expression of Oct-4 confirming their loss of
pluripotency. In addition, hESC-derived cells expressing high levels
of SMC markers had no expression of PECAM-1 (endothelial cell
marker) and a-actinin (a marker of cardiomyocytes) (data not
shown) confirming again their SMC differentiation.
Next, the expression and filament organization of contractile
proteins was evaluated in cell populations having similar or higher a-
SMA and SM-MHC gene expression than hVSMCs, i.e., CD34+RA,
CD34+PDGFBB, CD34
+KDR2PDGFBB and CD34
+KDR2EGM-
2. All hESC-derived cells stained positive for a-SMA, SM-MHC and
calponin (Figure S1 and Figure S2). More than 70% of the cells
expressed a-SMA as evaluated by FACS analyses (Figure S3).
hESC-Derived Smooth Muscle Cells
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Individualized calponin filaments were observed in 16 to 60% of the
overall cells; however, organized a-SMA protein filaments were only
observed in CD34+PDGFBB (6.0%) and CD34
+KDR2EGM-2
(6.1%) cells, and no organized SM-MHC filaments were observed
in the hESC-derived populations (Figure S3). In contrast, hVSMCs
expressed high levels of organized a-SMA (84.6%), SM-MHC
(94.6%) and calponin (80.1%) filaments.
Collectively, gene and protein analyses indicate that several
inductive signals (PDGFBB, or RA or EGM-2 basal medium) are
able to drive the SMC differentiation of CD34+ or CD34+KDR2
cells, characterized by variable expression of SMC proteins and
minimal assembly of the a-SMA protein into filaments.
Some hESC-derived cells present a secretion profile
similar to hVSMCs
Using the multiplex cytometric bead array method we investi-
gated the secretion of 17 analytes by hVSMC, CD34+PDGFBB,
CD34+RA, CD34+KDR2PDGFBB, CD34
+KDR2EGM-2 and
CD342PDGFBB cells. Out of the 17 analytes analyzed, hVSMCs
secreted IL-6, IL-7, IL-8, G-CSF, IFN-c, MCP-1 (MCAF) and
TNF-a, above the detection limit (.0.2 pg/mL) (Figure 3).
Cytokines IL-6 and IL-8 were the most secreted cytokines.
CD34+PDGFBB and CD34
+KDR2EGM-2 cells secreted the same
analytes as hVSMCs. CD34+KDR2PDGFBB and CD34
2PDGFBB
cells did not secrete IL-7, while CD34+RA cells secreted all seven
Figure 1. The effect of initial cell population and inductive signals on cell proliferation. (A) Protocols adopted to drive the differentiation
of CD34+, CD34+KDR2 and CD342 cells isolated from EBs at day 10 into the SMC lineage. (B) Flow cytometric analysis of hES-derived cells: CD342
(B.1), CD34+ (B.2) and CD34+KDR2 (B.3) cells (in this last case isolated from the CD34+ cell population). The results show that CD342 cells do not
express CD34+ marker (B.1), CD34+ cells are formed by CD34+KDR2 and CD34+KDR+ cells (B.2), and CD34+KDR2 do not express the KDR marker (B.3).
Percent of positive cells (dash plot) were calculated based in the isotype controls (grey plot). (C) Time-course proliferation of CD34+ (C.1), CD34+KDR2
(C.2) and CD342 cells (C.3).
doi:10.1371/journal.pone.0017771.g001
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Figure 2. Gene expression in hESC-derived cells evaluated by qRT-PCR. Gene expression in each experimental group was normalized by the
corresponding gene expression observed in hVSMCs. Oct-4 was normalized by the expression in undifferentiated hESCs. (A) Gene expression of hESCs,
CD34+ and CD342 cells before differentiation. SMa-22 expression in CD342 cells is very low (,8.561026) and not visible in the graph. CD34+ (B),
CD34+KDR2 (C), and CD342 (D) cells were cultured in SMGM-2medium, EGM-2medium, and EGM-2medium supplementedwith PDGFBB or TGFb-1 or RA
or TGFb-1 plus PDGFBB. Cells were characterized at passage 4 (<20 days). Results are Mean 6 SEM (n=4); * denotes statistical significance (P,0.05).
doi:10.1371/journal.pone.0017771.g002
hESC-Derived Smooth Muscle Cells
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cytokines mentioned and 4 cytokines more (IL-1b, IL-2, IL-4 and
GM-CSF) (Figure S4).
Interestingly, the secretion profile of CD34+PDGFBB cells is
very similar to the one observed for hVSMCS, either in the type
and concentration of the analytes secreted (Figure 3). In contrast,
CD342PDGFBB cells secreted analytes at different concentration
than hVSMCs, and the other cell populations seemed to be in an
intermediate stage in terms of secretion profile (Figure 3 and
Figure S4). CD34+RA cells secreted higher levels of cytokines
than all the remaining cell populations, including hVSMCs.
Some hESC-derived cells like hVSMCs have the ability to
contract when treated with vasoactive agonists and the
process is mediated by Ca2+
The ability of SMCs to contract in response to vasoactive
agonists is mediated by an increase of intracellular Ca2+ levels
which triggers the SMC contractile apparatus [26]. To evaluate
whether hESC-derived cells had contractility mediated by Ca2+,
the cells were loaded with FURA-2, a Ca2+ sensitive dye, and their
response to vasoactive agonists (bradykinin, angiotensin II,
carbachol and histamine) and depolarization agents (KCl) was
monitored by fluorescence (Figure 4A). The response profile was
compared to the one observed for hVSMCs and human umbilical
vein endothelial cells (HUVECs), as positive and negative controls,
respectively. Intracellular free Ca2+ [Ca2+]i levels increase when
hVSMCs are exposed to bradykinin, angiotensin II and carbachol,
while no measurable effect is observed in HUVECs. KCl induces a
higher increase in the [Ca2+]i levels in HUVECs than in hVSMCs,
while histamine induces similar levels of [Ca2+]i in both cell types
but following different profiles. These response patterns are typical
for HUVECs and hVSMCs [27,28,29,30,31].
CD34+RA and CD34+PDGFBB cells exposed to histamine,
bradykinin, angiotensin II, carbachol or KCl had similar response
profiles as observed for hVSMCs (Figure 4A and Figure S5). For
bradykinin and KCl the response intensity was lower than in
Figure 3. Secretomic profile of hVSMC and hECS-derived cells. Seventeen cytokines were measured simultaneously in medium collected
from hVSMC, CD34+PDGFBB, CD34
+RA, and CD342PDGFBB cells at passage 4. Results are Mean 6 SEM (n= 3).
doi:10.1371/journal.pone.0017771.g003
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hVSMCs, however similar intensity was observed for angiotensin II,
carbachol and histamine. On the other hand, although
CD34+KDR2RA, CD34+KDR2PDGFBB and CD34
+KDR2
EGM-2 cells had similar response profiles as hVSMCs, in general
the intensity of response was lower (Figure S6). In contrast to the
previous hESC-derived populations, CD342PDGFBB cells showed a
very low variation in the intracellular levels of Ca2+ when exposed to
depolarization and vasoactive peptides.
To examine whether hESC-derived cells were able to contract,
they were subjected to the effects of carbachol and atropine
(Figure 4B). With the exception of CD342PDGFBB cells, all cells
were able to contract after exposure to carbachol (13 to 38%
contraction after 30 min, depending on the cell population). In
most cases, cell contraction was not significantly different (P.0.05)
from the one observed for hVSMCs. Moreover, with the exception
of CD342PDGFBB cells, the muscarinic inhibitor atropin
significantly blocked or reduced the carbachol-mediated effect
(P,0.05) (Figure 4B).
Based on the expression of SMC proteins and genes, secretion of
cytokines and cellular contraction, CD34+PDGFBB and CD34
+RA
cells were selected for further characterization. These cells are likely
at a smooth muscle progenitor cell stage (SMPCs), which can
potentially be further induced into a more mature SMC phenotype.
The contraction of both hESC-derived SMPCs and
hVSMCs involves Rho A/Rho kinase- and Ca2+/CaM/
MLCK-dependent pathways
CaM/MLCK- and RhoA/Rho kinase-dependent pathways
play a pivotal role in SMC contraction [7,26]. The Ca2+/CaM
pathway plays a key role in SMC contraction through the
stimulation of MLCK-mediated phosphorylation of myosin light
chain 20,000 Da (MLC20) [26]. To assess whether Ca
2+/CaM
pathway was involved in the contraction of hESC-derived SMPCs,
cells were exposed to the CaM-specific inhibitor W-7 [32], and
then contraction was induced by exposing them to the CaM
agonist U46619 [7]. To facilitate the evaluation of cell contraction,
cells were encapsulated in fibrin gels, and gel diameter was
determined after 14 h. Pre-incubation of hESC-derived SMPCs
with W-7 significantly inhibited U46619-induced contraction
(Figure 5A and Figure 5B). Similar results were obtained for
the control cells hVSMCs. Overall the results indicate the
involvement of CaM/MLCK-kinase pathway in cell contraction.
To examine whether Rho kinase was involved in the hESC-
derived SMPC contraction, the cells were pre-treated with the
Rho kinase-specific inhibitor Y27632 [7] and then contraction was
induced by the agonist End-1 [33]. Cells treated with Y27632 and
End-1 showed no significant contraction (Figure 5A and
Figure 5B). In contrast, cells treated with End-1 but not
Y27632 contracted significantly. Similar response profiles were
obtained for hVSMCs and hESC-derived SMPCs. Collectively the
results indicate the involvement of a Rho/Rho kinase-dependent
pathway in SMC contraction.
3D culture of hESC-derived SMPCs modulates gene
expression towards the expression observed in hVSMCs
We investigated the use of hESC-derived SMPCs for tissue
engineering applications [2,3]. Fibrin gels previously used for the
encapsulation of neonatal SMCs [34] were selected as scaffolds for
the encapsulation of SMPCs. These gels allow cell attachment and
can be remodeled by cellular metalloproteinases. SMPCs were
encapsulated in fibrin gels for 3 days after which the cells were
characterized at protein and gene levels.
Gene expression of SMPCs (CD34+RA and CD34+PDGF) was
compared to hVSMCs under the same culture conditions
(Figure 6A and Figure 6B). The culture of SMPCs in 3D gels
modulated the expression of SMC genes (a-SMA, SM-MHC or
SMa-22) towards the one observed for hVSMCs cultured in 3D
gels. We complemented these studies by evaluating the expression
of extracellular matrix and adhesion molecules by a quantitative
real-time PCR array. This array evaluated the expression of 84
genes involved in cell-cell and cell-matrix interactions. Again, the
3D culture of SMPCs modulated extracellular matrix and
adhesion molecule genes towards the expression observed in
hVSMCs (Figure 6B). The number of genes with similar
expression increased from 23 to 58 or 9 to 53 when
CD34+PDGFBB cells or CD34
+RA cells are cultured in 2D or
3D, respectively. Finally, gene expression associated with SMCs
including collagen I and thrombospondin 1 [35], integrins a2, a3,
a5, aV and b1 [36], the enzyme metalloproteinase 2 [37], and the
growth factor TGFb-1 was similar in SMPCs and hVSMCs
(Figure 6C and Figure S7).
Co-culture of hESC-derived SMPCs with hVSMCs induces
the assembly of a-SMA and calponin into filaments
Next we sought to investigate whether hESC-derived SMPCs
could be further matured into a SMC phenotype with an organized
contractile filament network. To accomplish this goal, hESC-
derived SMPCs were initially labeled with PKH67 fluorescent dye
and co-cultured on top of hVSMCs for 5 days. After this time, the
cells were sorted and characterized by immunocytochemistry.
Remarkably, hESC-derived SMPCs showed significant improve-
ment in the organization of the fibers after contact with hVSMCs:
36.3% and 41.2% of CD34+PDGFBB and CD34
+RA cells,
respectively, had organized a-SMA fibers, while 64.8% and
73.8% had organized calponin fibers (Figure 7A and
Figure 7B). These results show that hESC-derived SMPCs are
plastic cells and can be induced to differentiate into a more mature
SMC phenotype displaying an organized contractile network.
Vasoactive agents U46619 and End-1 improve the
organization of contractile protein fibers
Next, we identified molecules able to maturate the hESC-
derived SMPCs into SMCs having an organized contractile
network. We sought to evaluate the effect of the agonists U46619
and End-1 involved in the CaM/MLCK- and RhoA/Rho kinase-
contraction pathways, respectively. In CD34+RA cells, each
agonist independently improved dramatically the organization of
a-SMA and calponin fibers, being End-1 the most effective. The
addition of both agonists did not significantly improve the effect of
End-1 (Figure 7C and Figure 7D). Importantly, the induction
effect of the vasoactive agents was not observed on
CD34+PDGFBB (Figure 7D) or CD34
2PDGFBB cells (Figure
S8) showing that the inductive effect is dependent on the
differentiation history of the SMPCs. The mature SMCs (derived
Figure 4. Contractility of hESC-derived cells. (A) Concentration of intracellular Ca2+ in FURA-2-loaded cultured hESC-derived cells in response to
several agonists (100 mM histamine, 1027 M bradykinin, 1025 M angiotensin II or 50 mM KCl). hVSMCs and HUVECs were used as positive and
negative controls, respectively. Traces are representative of 4 independent experiments for each condition. (B) Contractility of hESC-derived cells
when exposed to the effects of carbachol (1025 M in DMEM medium, for 30 min) or atropine (1024 M, 1 h) plus carbachol (1025 M for 30 min).
hVSMCs were used as controls. Results are Mean 6 SEM (n= 3); # denotes statistical significance (P,0.05) in the same experimental group.
doi:10.1371/journal.pone.0017771.g004
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from CD34+RA) express SMC markers including a-SMA, SM-
MHC and calponin but not the cardiac marker a-actinin (Figure
S9). Furthermore, the cells show no expression of troponin T, a
protein found in skeletal and cardiac muscle but not in smooth
muscle and vascular endothelial-cadherin, a protein typically
expressed in endothelial cells (Figure S10).
Discussion
In this study, we demonstrate that CD34+ cells have higher
SMC potential than CD342 cells. We further show that RA or
PDGFBB drive the differentiation of CD34
+ cells into SMPCs We
have characterized the differentiated cells at gene and at protein
level, their secretome, the ability to contract when incubated with
several pharmacological agents, and contraction mechanism
mediated by Ca2+. Envisioning the use of these cells for vascular
engineering, they were encapsulated on 3D fibrin scaffolds and
characterized at gene and functional levels. Finally, we identified
End-1 as a key molecule to induce the polymerization of
contractile proteins in SMPCs (CD34+RA cells).
We examined the capacity of three hESC populations (CD34+,
CD34+KDR2, CD342) isolated from EBs at day 10, and cultured
Figure 5. Evaluation of the role of Rho A/Rho kinase- and Ca2+/CaM/MLCK-dependent pathways in the contraction of SMPCs and
hVSMCs. CD34+PDGF or CD34+RA cells were initially treated for 3 days with serum-free medium containing the agonists endothelin-1 (End-1
(10 nM), A and B.1) or U46619 (1 mM) (A and B.2) in the presence or absence of the Rho-kinase inhibitor Y27632 (13 mM) or the calmodulin inhibitor
W-7 (12 mg/mL). The cells were then encapsulated in fibrin gels and the diameter of the gel assessed at time 0 (1) and 14 h (2,3,4). Graph displays the
variation in gel diameter (percentage) encapsulating hVSMCs (2), CD34+PDGFBB cells (3) or CD34
+RA cells (4). Data are shown as mean6 SEM (n= 6),
* P,0.001 relatively to samples inhibited with Y27632 or W-7, by Student’s t-test.
doi:10.1371/journal.pone.0017771.g005
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as single cells on media supplemented with inductive signals
including PDGFBB, RA, TGFb-1 and TGFb-1 plus PDGFBB to
differentiate into SMCs. Notably, TGFb-1 [5,21,38], PDGFBB
[5,12,19], and RA [9,17] have been reported to be very important
inductive signals for SMC differentiation from different initial stem
cell populations. We report that from all inductive signals tested in
this study, RA and PDGFBB are the most effective in guiding the
differentiation of hESC-derived CD34+ cells into SMPCs, based
on gene and protein analysis, response to the depolarization agents
and vasoactive peptides, contraction profile, secretion of cytokines,
and behavior in a 3D scaffold. Although SMPCs express most of
the SMC markers, they exhibit disorganized contractile proteins.
We further show that CD34+ cells have higher propensity to
yield contractile SMPCs than CD342 cells, when exposed to the
same inductive signals. Interestingly, CD34+KDR2 cells which
have been reported to be of mesenchymal origin [18], can give rise
to SMPCs but they respond less efficiently to vasoactive peptides
and depolarization agents, have lower contractile properties than
Figure 7. Maturation of hESC-derived SMPCs. (A and B) Expression and organization of SMC proteins on hESC-derived SMPCs cultured on top
of inactivated-hVSMCs for 5 days. hVSMCs were used as controls. Bar corresponds to 50 mm. Results are Mean 6 SEM (n= 10). (C and D) Expression
and organization of SMC proteins on hESC-derived SMPCs treated with vasoactive agents for 3 days. Bar corresponds to 50 mm. Results are Mean 6
SEM (n= 8); *, **, *** denote statistical significance (P,0.05, P,0.01, P,0.001, respectively).
doi:10.1371/journal.pone.0017771.g007
Figure 6. Characterization of hESC-derived SMPCs encapsulated in 3D fibrin gel scaffolds. SMPCs were characterized after being
encapsulated in fibrin gels for 3 days. (A) SMC gene expression on CD34+RA (A.1) and CD34+PDGF (A.2) cells, as assessed by qRT-PCR. Gene
expression of hESC-derived SMPCs was normalized by gene expression of hVSMCs under the same culture conditions. Results are Mean6 SEM (n= 4).
(B) Comparison of extracellular matrix and adhesion molecules-related gene expression in CD34+PDGFBB (B.1) or CD34
+RA cells (B.2) with hVSMCs
cultured in 2D (tissue culture polystyrene) or cultured in 3D fibrin gels. Gene expression was evaluated using a RT2 ProfilerTM PCR array.
(C) Normalized extracellular matrix and soluble factor gene expression of SMPCs relatively to hVSMCs, both cultured in 3D or 2D systems.
doi:10.1371/journal.pone.0017771.g006
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CD34+PDGF cells, and have a different cytokine secretion profile
as compared to hVSMCs. In line with previous results [39], our
results suggest that cells expressing KDR receptor are needed for
an efficient SMC differentiation.
The development of mature contractile SMCs from stem cells
occurs in multiple steps comprising (i) the commitment to the
SMC lineage, (ii) the differentiation into early immature and (iii)
the maturation into the mature contractile phenotype [40].
Previously, we have reported that CD34+ cells could give rise to
SMLCs when cultured in medium supplemented with PDGFBB;
however, the differentiation of SMLCs was not complete since the
assembly of a-SMA or SM-MHC proteins into filaments was not
observed [12]. Curiously, similar results have been obtained in this
work for the cell populations tested and exposed to different
inductive signals including RA and TGFb-1.
Our results indicate that the co-culture of SMPCs with fully
differentiated hVSMCs induces the assembly of a-SMA and
calponin proteins into individualized filaments. This indicates that
the cells are able to maturate into a fully contractile phenotype. It
is known that both assembly and disassembly of actin filaments is
regulated by RhoA [41]. Consistent with this, our results show that
End-1, an agonist of RhoA pathway, dramatically increases actin
polymerization in CD34+RA cells and the cells exhibit individu-
alized a-SMA and calponin filaments. However, such inductive
effect was not observed in CD34+PDGFBB cells, and this could be
due to the inhibition of mature SMC marker expression by
PDGFBB [42]. Strikingly, these cells are contractile (Figure 5)
despite presenting a small percentage of polymerized actin fibers
(6%; Figure S3). Nevertheless, it is known that the total amount
of actin that undergoes polymerization after induction of
contraction is relatively small [43]. Further research is needed to
study the molecular processes that regulate the assembly of actin
filaments in smooth muscle tissues and the nature of the actin
filaments network that are formed during contractile activation
[43].
Contractile and synthetic SMCs, which represent the two ends
of a spectrum of SMCs with intermediate phenotypes, clearly show
different morphologies [22]. The SMPCs derived in this work
seem to have the contractile phenotype, as they are spindle-shaped
[44], express proteins involved in SMC contraction including a-
SMA, SM-MHC, calponin and SMa-22 [22,24], and contract
when exposed to carbachol and vasoactive peptides being this
effect reversed by the presence of the respective antagonists.
We show that SMPCs are able to contract to a plethora of
vasoactive agents including carbachol, angiotensin II, histamine,
thromboxane-mimetic U46619, endothelin-1, and bradykinin, as
hVSMCs. Most of these agonists act through different receptors
coupled to G-proteins activating membrane-bound phospholipase
C, which leads to the formation of inositol-1,4,5-triphosphate (IP3)
and diacylglycerol (DAG) [26]. Through different mechanisms,
both molecules induce the accumulation of Ca2+ in the cell
cytoplasm [26]. The increase of intracellular Ca2+ activates the
cell’s contraction machinery. Our results agree with previous ones
showing that hESC-derived SMCs respond to bradykinin,
histamine and carbachol by increasing at different levels the
intracellular concentration of Ca2+[14]. The accumulation of
intracellular Ca2+ in hESC-derived SMCs exposed to carbachol is
minimal, indicating that the contraction of the cell may involve the
activation of other intracellular players (e.g. protein kinase C) than
Ca2+, as described in other studies [45].
Our results show that hESC-derived SMPC contraction is
mediated by the activation of CaM/MLCK- and Rho/Rho
kinase-dependent pathways [7,26]. A similar mechanism has
been reported recently for SMLCs obtained from human adipose
tissue-derived mesenchymal stem cells [7]. The results also
indicate that the absence of fully organized protein filaments did
not prevent the contraction of SMLCs. This is in line with results
reported previously by us [12] and by others [13] despite the
absence of maturity and organization in the contractile
machinery of the cell.
SMCs have key biological functions in terms of contraction and
secretion of soluble signaling molecules [46]. In the present study
we report for the first time the secretion profile of hES-derived
SMPCs. CD34+ cells that differentiate in medium supplemented
with PDGFBB have similar secretome profile as hVSMCs. They
express high levels (.100 pg/mL) of IL-6 and IL-8, moderate
levels (between 100 and 10 pg/mL) of IFN-c, and small levels of
(between 10 and 1 pg/mL) of IL-7, G-CSF, MCP-1 and TNF-a.
IL-6 is a cytokine with potent inflammatory properties and
metabolic effects in SMCs. It has been shown that IL-6 secretion is
inversely correlated to glucose consumption [47]. IL-8 is a
cytokine that induces the proliferation and chemotaxis of smooth
muscle cells and increases the activity of mitogen-activated protein
kinase (MAPK) [48]. IFN-c acts on vascular smooth muscle cells to
induce cellular proliferation [49].
Although several studies have reported the differentiation of
different stem cells into SMCs, very few evaluated the impact of
the 3D environment at the geno- and phenotype of the
differentiated cells [5]. Gene studies have demonstrated that
human aortic SMCs encapsulated in a 3D collagen matrix have
significantly less focal adhesions, lower proliferation, and lower a-
SMA expression than cells in 2D [50]. However, to our
knowledge, no study has compared the gene expression of
SMLCs from different origins with fully differentiated SMCs
when cultured in 2D or 3D systems. Our results show that hESC-
derived SMPCs encapsulated for 3 days in fibrin gels express
similar gene levels of a-SMA, SM-MHC, and SMa22 as
encapsulated hVSMCs. In addition, considering an array of 84
genes related to cell-cell and cell-matrix interactions, 3D-
cultured-SMPCs had a more hVSMC-similar gene expression
profile than 2D-cultured SMPCs. This shows that 3D scaffolds
may induce further the differentiation of SMPCs into SMCs.
Several factors might account for the differences found between
2D and 3D culture systems including (i) ECM stiffness and (ii)
ECM 3D environment. It has been demonstrated that the
stiffness of the ECM has a high impact in the cytoskeletal and
focal adhesion assembly of SMCs [51]. Furthermore, SMCs
cultured within 3D polyethylene glycol-fibrinogen [52] or
collagen [50] gels had less proliferation, stress fibers and focal
adhesion than on 2D culture systems. Future studies should
evaluate the effect of both factors in the modulation of geno- and
phenotype of the differentiated cells over the time and study the
underlining mechanism. In this study we assessed the effect of the
3D matrix after 3 days of cell encapsulation. During this time,
previous studies have shown that SMCs are able to migrate and
remodel the ECM [53]; however, it would be interesting to
extend these studies in time.
Although very recent studies have identified and characterized
hESC-derived populations with SMC potential [13,14], identified
bioactive agents involved in their SMC differentiation, and
evaluated their functionality, our study advance these results in
several ways. First, it provides a detailed analysis of the phenotype,
secretome and function (unraveling the mechanism of cell
contraction) of hESC-derived SMCs at levels not documented
before. In contrast to the previous studies that have used
monolayer-based differentiation protocols, our methodology uses
an EB-differentiation step to isolate progenitor cells, which might
have advantages for the scale-up of the process through the use of
hESC-Derived Smooth Muscle Cells
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bioreactors. Second, our study identifies a methodology to induce
the organization of the contractile protein filaments. Third, it
demonstrates the importance of a 3D environment to modulate
the activity of hESC-derived SMLCs.
Recent studies reported the derivation of pluripotent stem cells
from human somatic cells by retroviral transduction [54]. These
reprogrammed cells share many features with hESCs in terms of
morphology, gene expression and differentiation potential, and
open a new avenue for the potential derivation of autologous cells
for regenerative medicine and drug screening. Indeed, the
differentiation of iPSCs into SMCs has been recently reported
[55]. It remains to be determined whether the methodology
described in this work can be applied on iPSCs and this is an issue
that will be evaluated in future work.
Supporting Information
Figure S1 SMC proteins are expressed on hESC-derived
SMPCs. CD34+, CD34+KDR2 and CD342 cells differentiated
under different media conditions express a-SMA, calponin and
SM-MHC, as evaluated by immunofluorescence. hVSMCs were
used as a positive control and HUVECs as a negative control for
the SMC markers. In all figures, bar corresponds to 50 mm.
(TIFF)
Figure S2 Isotype controls for SMPC immunostainning.
Stained the isotype controls IgG2A and IgG1 for the SMC markers:
a-SMA, SM-MHC and Calponin. Cell nuclei were stained with 49,
69-diamidino-2-phenylindole (DAPI). Cells were labeled with mouse
anti–human IgG2A and IgG1 antibodies. Bar corresponds to 50 mm.
(TIFF)
Figure S3 Organization and expression of contractile
proteins. (A) Quantification of organized a-SMA, SM-MHC and
calponin filaments. (B) Expression of a-SMA in differentiated
CD34+, CD34+KDR2 and CD342 cells. Cells were differentiated
for 3 passages (approximately 18 days after cell seeding). hVSMCs
and HUVECs were used as positive and negative controls,
respectively. In all graphs, the percentages of positive cells were
calculated based in the isotype controls (gray plot) and are shown
in each histogram plot.
(TIFF)
Figure S4 Secretomic profile of hESC-derived cells. 17
cytokines were measured simultaneously in the medium collected
from CD34+KDR2PDGFBB and CD34
+KDR2EGM-2 cells. A
standard range of 0.2 to 3,200 pg/mL was used. Samples and
controls were run in triplicate, standards and blanks in duplicate.
(TIFF)
Figure S5 Contractility of hESC-derived cells. Cells were
loaded with FURA-2/AM and their response to carbachol
(1025 M) was monitored by fluorescence. The response profile
was compared to the one observed for hVSMCs and HUVECs, as
positive and negative controls, respectively.
(TIFF)
Figure S6 Contractility of hESC-derived cells. Cells were
loaded with FURA-2/AM and their response to vasoactive agonists
(bradykinin (1027 M), angiotensin II (1025 M) and histamine
(100 mM) and depolarization agents (KCl; 50 mM) was monitored
by fluorescence. The response profile was compared to the one
observed for hVSMCs and HUVECs, as positive and negative
controls, respectively.
(TIFF)
Figure S7 Integrin gene expression. Gene expression on
CD34+PDGFBB and CD34
+RA cells was normalized by gene
expression on hVSMCs, both cultured in 3D or 2D systems. Gene
expression was obtained from the RT2 ProfilerTM PCR array.
(TIFF)
Figure S8 Expression and organization of SMC proteins
on CD342PDGFBB cells treated with vasoactive agents
for 3 days. A) Quantification by immunocytochemistry analysis.
Results are Mean 6 SEM (n = 8). B) Expression of a-SMA and
calponin in CD342PDGFBB cells treated with End-1 (10 nM) for 3
days. Bar corresponds to 50 mm.
(TIFF)
Figure S9 Gene expression in CD34+PDGFBB and
CD34+RA cells after treatment with vasoactive agents
for 3 days. Gene expression in CD34+PDGFBB and CD34
+RA
cells was normalized by gene expression in hVSMCs. Results are
Mean 6 SEM (n = 4).
(TIFF)
Figure S10 Expression and organization of troponin T
(TrpnT) and vascular endothelial-cadherin (VECad) on
CD34+RA (A) and CD34+PDGFBB (B) cells treated with
End-1 for 3 days. Human cardiac tissue (for TrpnT) and
HUVECs (for VeCad) were used as positive controls. Bar
corresponds to 50 mm.
(TIFF)
Table S1 Primers used for Real Time PCR. PCR
conditions: initial denaturation step at 94uC for 5 min; 40 cycles
of denaturation at 94uC for 30 sec, annealing at 60uC for 33 sec
and extension at 72uC for 30 sec. At the end was performed a final
7 minutes extension at 72uC. After amplification, the melting
curve profile or agarose gel electrophoresis was used to determine
the specificity of PCR products.
(TIFF)
Materials and Methods S1
(DOC)
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